Acceleron Announces Presentation of Sotatercept Data at the American Society of Nephrology Kidney Week 2015
02 Octubre 2015 - 8:20AM
Business Wire
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, today reported that its collaboration
partner, Celgene, and investigators on the sotatercept program will
present preclinical and interim clinical data at the American
Society of Nephrology (ASN) Kidney Week 2015, being held in San
Diego, CA on November 3-8, 2015.
Preliminary data from ongoing Phase 2a clinical studies of
sotatercept in End-Stage Kidney Disease patients, including effects
on hemoglobin, vascular calcification, bone mineral density and
safety and tolerability, will be presented on Thursday and Friday,
November 5 and 6, 2015. Additionally, data from preclinical studies
will be presented on Friday and Saturday, November 6 and 7,
2015.
Thursday, November 5, 2015, from 10:00 AM – 12:00 PM (PST)
- “Sotatercept Improves Anemia, Vascular
Calcification, and Bone Loss in Patients With End-Stage Kidney
Disease on Hemodialysis” (clinical poster presentation
(TH-PO038))
Friday, November 6, 2015, from 4:30 PM – 6:30 PM (PST)
- “Safety and Hemoglobin Effect of
Sotatercept, Administered Intravenously and Subcutaneously, for
Maintenance of Hemoglobin in Hemodialysis Subjects: Interim
Analysis of a Phase 2 Study” (clinical oral presentation
(FR-OR020))
- “The Role of Activin in the CKD-MBD”
(preclinical oral presentation (FR-OR021))
Saturday, November 7, 2015 from 10:00 AM – 12:00 PM (PST)
- “Kidney Injury/Repair Stimulates
Vascular Disease Through Activin and Systemic Wnt Inhibition”
(preclinical poster presentation (SA-PO1068))
The clinical presentations will be available on Acceleron’s
website (www.acceleronpharma.com) in the “Publications” tab when
presented at Kidney Week 2015.
About Sotatercept
Sotatercept is an activin receptor type IIA fusion protein that
acts as a ligand trap for members in the Transforming Growth
Factor-Beta (TGF-β) superfamily involved in the late stages of
erythropoiesis (red blood cell production). Sotatercept regulates
late-stage erythrocyte (red blood cell) precursor cell
differentiation and maturation. This mechanism of action is
distinct from that of erythropoietin (EPO), which stimulates the
proliferation of early-stage erythrocyte precursor cells. Acceleron
and Celgene are jointly developing sotatercept as part of a global
collaboration. Sotatercept is currently in multiple phase 2
clinical trials. For more information, please visit
www.clinicaltrials.gov.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
therapeutic candidates that regulate cellular growth and repair.
The company is a leader in understanding the biology of the
Transforming Growth Factor-Beta (TGF-beta) protein superfamily, a
large and diverse group of molecules that are key regulators in the
growth and repair of tissues throughout the human body, and in
targeting these pathways to develop important new medicines.
Acceleron has built a highly productive R&D platform that has
generated innovative clinical and preclinical therapeutic
candidates with novel mechanisms of action. These therapeutic
candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151002005405/en/
Acceleron Pharma Inc.Todd James, 617-649-9393Senior Director,
Corporate CommunicationsorMedia:Suda Communications LLCMaureen L.
Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024